Unique ID issued by UMIN | UMIN000036522 |
---|---|
Receipt number | R000041584 |
Scientific Title | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug |
Date of disclosure of the study information | 2019/04/16 |
Last modified on | 2020/04/15 12:07:30 |
Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug
Clinical trial for PSP using anticholinergic drug
Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug
Clinical trial for PSP using anticholinergic drug
Japan |
Progressive supranuclear palsy
Neurology |
Others
NO
Efficacy of trihexyphenidyl hydrochloride for freezing symptoms (akinesia) due to progressive supranuclear palsy
Safety,Efficacy
Difference of summation of scores 13-15, and 29-30 items of UPDRS and 2.12-2.13 items of MDS-UPDRS between pretreatment and 3 months after the treatment
Score of PSPRS, MMSE, FAB, MoCA, volume of voice, voice duration, timed up & go test, score of FOGQ, modified Schwab & England ADL scale, frequency of urination, and side effect
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Medicine |
Trihexyphenidyl hydrochloride max.3mg for 3 months
Placebo max. 3mg for 3 months
40 | years-old | <= |
Not applicable |
Male and Female
1)>=40 years old patient with progressive supranuclear palsy (PSP) when obtained informed consent
2) sporadic PSP
3) slowly progressive course
4)patient with freezing gait: the patients meet MDS-PSP criteria such as [probable PSP-RS(O1 or O2)+(P1 or P2), probable PSP-PGF (O1 or O2)+A1, possile PSP-RS (O2 +P3) or possible PSP-PGF A1]
5) severity of PSP 1-5 (except for 6)
6) >=15 points of MMSE score
7) existence of reliable care giver for the patient
8) researcher can obtain the written consent from the patient.
Included a patient who meets the aobove mentioned all items.
1) attending other clinical trials
2) alcohol dependence or drug abuser
3) psychiatric disorder
4) allergy for anti-cholinergic drugs
5) severe liver or renal dysfunction
6) effective for levodopa, and/or using following drugs: anti-psychiatric agents, anti-epileptic drugs, acethycholine esterase inhibitor, memantine, immunosuppressant, corticosteroids, anti-coagulant, lithium, or anti-cholinergic drug
7) not suitable for clinical trial judged by principal investigator or researchers.
32
1st name | Takayoshi |
Middle name | |
Last name | Shimohata |
Gifu University Graduate School of Medicine
Department of Neurology
5011194
1-1 Yanagido, Gifu
058-230-6000
shimohata@gmail.com
1st name | Yuichi |
Middle name | |
Last name | Hayashi |
Gifu University Graduate School of Medicine
Department of Neurology
501194
1-1 Yanagido, Gifu
0582306254
http://www.med.gifu-u.ac.jp/neurology/research/psp.html
hayashiy@gifu-u.ac.jp
1) Department of Neurology, Gifu University Graduate School of Medicine,
2) National Hospital Organization, Higashi Nagoya Hospital
None
Self funding
Gifu University Graduate School of Medicine
1-1 Yanagido, Gifu
058-230-6000
rinri@gifu-u.ac.jp
NO
岐阜大学医学部附属病院(岐阜県)/Gifu University Hospital
国立病院機構 東名古屋病院(愛知県)/National Hospital Organization Higashi Nagoya Hospital
2019 | Year | 04 | Month | 16 | Day |
Unpublished
Open public recruiting
2019 | Year | 04 | Month | 03 | Day |
2019 | Year | 04 | Month | 03 | Day |
2019 | Year | 04 | Month | 15 | Day |
2022 | Year | 03 | Month | 31 | Day |
2019 | Year | 04 | Month | 15 | Day |
2020 | Year | 04 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041584